Skip to main content

Foresite Capital — Portfolio, Page 4

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

129
Companies
$15.2B
Total invested
$143.0M
Avg. check
19
Industries
Biotechnology 21Health Care 19Medical 13Therapeutics 12Life Science 7Pharmaceutical 5+13 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 7396 of 129
Midi Health
February 2026

Midi Health provides virtual care for women in midlife, offering clinician support for menopause, hormonal health, and related conditions.

Health Care · Palo Alto$100.0M Series D
Vaxcyte
January 2026

Vaxcyte focuses on developing vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.

Biopharma · San Carlos$632.5M Post Ipo Equity
bit.bio
January 2026

Bit.bio provides engineered human cell products and platform services for biomedical research, drug discovery, and cell therapy development.

Biotechnology · Cambridge$50.0M Series C
Alumis
January 2026

Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.

Biotechnology · San Francisco$345.1M Post Ipo Equity
Aeovian Pharmaceuticals
December 2025

Aeovian Pharmaceuticals aims to discover, develop, and commercialize therapeutics for the treatment of rare and age-related diseases.

Biopharma · San Francisco$55.0M Series B
Myome
December 2025

Myome helps identify genes that cause disease and act based on leading science.

Biotechnology · Palo AltoSeries Unknown
Wave Life Sciences
December 2025

Wave Life Sciences is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling diseases

Biotechnology · Boston$350.0M Post Ipo Equity
Invivyd
November 2025

Invivyd develops antibodies to transcend the limitations of the human immune system and fight against viral infections.

Biotechnology · Waltham$125.0M Post Ipo Equity
Indomo
October 2025

Indomo is a clinical-stage firm that aims to improve access to quality healthcare through novel device-enabled treatments.

Biotechnology · San Francisco$25.0M Seed
Tango Therapeutics
October 2025

Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.

Biotechnology · Cambridge$197.0M Post Ipo Equity
Nurix Therapeutics
October 2025

Nurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs.

Biotechnology · San Francisco$250.0M Post Ipo Equity
Rapt Therapeutics
October 2025

Rapt is focused on the discovery and development of novel small-molecule agents to activate the immune system to eradicate cancer.

Biotechnology · South San Francisco$250.0M Post Ipo Equity
AtaiBeckley
October 2025

AtaiBeckley develops innovative mental health treatments that address significant unmet medical needs.

Biotechnology · Berlin$149.5M Post Ipo Equity
Thyme Care
September 2025

Thyme Care is a healthcare company that provides oncology care management services.

Health Care · Nashville$97.0M Series D
Avenzo Therapeutics
September 2025

Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment.

Biotechnology · San Diego$60.0M Series B
Korsana Biosciences
September 2025

Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases including Alzheimer’s.

Biopharma · Waltham$150.0M Series A
Kriya Therapeutics
August 2025

Kriya Therapeutics is a biopharmaceutical company that develops gene therapies for ophthalmology, neurology, and metabolic diseases.

Biotechnology · Palo Alto$320.8M Series D
Quantum SI
July 2025

Quantum SI offers Next Generation Protein Sequencing that makes diagnostics digital.

Biotechnology · Guilford$50.0M Post Ipo Equity
RayThera
April 2025

RayThera is dedicated to developing small molecule therapies specifically targeting unmet needs in immunology.

Biotechnology · San Diego$110.0M Series A
Latigo Biotherapeutics
March 2025

Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain.

Biotechnology · Thousand Oaks$150.0M Series B
Eikon Therapeutics
February 2025

Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.

Biotechnology · Hayward$350.7M Series D
Abcuro
February 2025

Abcuro develops immunotherapies to treat autoimmunity and cancer.

Biotechnology · Newton$200.0M Series C
Sollis Health
December 2024

Sollis Health offers concierge medical centers that provide on-demand care for families, including same-day visits and virtual care options.

Health Care · New York$33.0M Series B
Replimune Group
November 2024

Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer.

Biotechnology · Woburn$140.0M Post Ipo Equity

Where Foresite Capital invests

Biotechnology21
Health Care19
Medical13
Therapeutics12
Life Science7
Pharmaceutical5

About Foresite Capital's portfolio

How many companies has Foresite Capital invested in?

Foresite Capital has invested in 129 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Foresite Capital invest in?

Foresite Capital's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Life Science. The firm invests across 19 different industry categories.

What is Foresite Capital's largest investment?

Among tracked funding rounds, Vaxcyte received $632.5M in a Post Ipo Equity round. Foresite Capital's total known invested capital is $15.2B.

What is the average investment size for Foresite Capital?

Foresite Capital's average investment size is $143.0M across its portfolio of 129 companies.

What are Foresite Capital's most recent investments?

Recent Foresite Capital portfolio additions include Midi Health, Vaxcyte, bit.bio, Alumis, Aeovian Pharmaceuticals. These companies were founded in 2020 or later.

Reach the founders behind these 129 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →